SETDB1 and cancer: Recent studies have shown that in a variety of cancers, multiple epigenetic modifiers, such as SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) and lysine‐specific demethylase 1A (LSD1), play critical roles in regulating the expression of endogenous antigens and immune responses.33